Lung administrations of antibiotics by nebulization are promising for improving treatment efficiency against pulmonary infections, as they increase drug concentration at sites of infection while minimizing systemic side effects. For low soluble molecules like rifampicin, cyclodextrins (CD) may improve lung delivery by permitting higher dosing. For this purpose, we investigated rifampicin-CD complexes in terms of rifampicin apparent solubility enhancement, effect on in vitro permeability on a Calu-3 broncho-alveolar model and of in vitro antibacterial activity against Acinetobacter baumannii. Complexation efficiency between rifampicin and hydroxypropyl-β-Cyclodextrin (HPβCD) or methylated β-cyclodextrin (RAMEB) was pH-dependent, involving the piperazin group. Rifampicin phase solubility diagrams constructed at pH 9 showed an A L -type curve for RAMEB and a B S -type for HPβCD. Stability constants calculated for a 1:1 molar ratio of CD/ rifampicin were 73.4 ± 8.2 M -1 for RAMEB and 68.5 ± 5.2 M -1 for HPCD. Complexes with HPCD or RAMEB increased 7.6 times and 22 times respectively the apparent solubility of rifampicin and were found to be satisfactorily stable for 2 days when diluted in a solution at physiological pH.
Introduction
Antibiotic overuse and misuse have led to the positive selection of bacteria which are resistant to most antibiotics. These multidrug-resistant (MDR) bacteria, mainly isolated in hospital units, are responsible for nosocomial infections that represent a physician's challenge throughout the world. Recently, Acinetobacter baumannii, responsible for hospital-acquired pneumonia, has emerged as one of the most ubiquitous antibiotic-resistant gram-negative nosocomial pathogens among critically ill patients [1] [2] [3] . Although typically used carbapenems, ampicillin-sulbactam, and amikacin have retained excellent in vitro and clinical activities against susceptible strains of A. baumannii, a growing number of reports indicates resistance to these antibacterials [4] [5] [6] [7] [8] . This gives rise to uncertainty about which antimicrobials should be chosen for treatment, resulting in increased patient mortality [9] .
As a result, older antibiotics, including colistin and rifampicin ( Fig. 1 ) are administered by intravenous route to treat patients infected with MDR A. baumannii [4, [9] [10] [11] . However, pulmonary infections do not always respond well to such systemic therapy, due to insufficient drug diffusion into pulmonary tissue and lumen [12, 13] . Bacteria that have persisted over treatment may develop resistance, but higher drug doses to compensate for poor diffusion may lead to systemic toxicity. Furthermore systemic antibiotic administration may not be justified for A. baumannii nosocomial pneumonia as these infections are generally limited to the pulmonary area. Additionally, most patients find difficult to adhere to treatments that necessitate several administrations a day to maintain efficient antibiotics concentration.
Therefore, it is imperative to develop new ways to deliver and use antibiotics to avoid the selection and spread of resistant A. baumannii and to improve patients' compliance by decreasing dosing frequency.
Antibiotic delivery systems administered as aerosols via the pulmonary route aim to deliver high drug concentrations directly at the site of infection while minimizing systemic biodistribution and toxicity. Rifampicin is a so-called concentration-dependent antibiotic [14] .
The rate and extent of bacterial kill is related to the attainment of sufficiently high maximum concentration (Cmax) relative to the minimal inhibitory concentration (MIC). Higher its concentration in targeted sites higher its bactericide activity. However, rifampicin has a rather low aqueous solubility (from 1.58 to 3.35 mg/mL at pH 7.4 [15, 16] ), limiting the possibility of achieving high concentration in the broncho-alveolar epithelium-lining fluid (ELF) when administered as aerosolized solution.
One way to enhance rifampicin (apparent) solubility is the use of cyclodextrins (CDs), as complexing and solubilizing agent. Cyclodextrins enhance aqueous apparent solubility due to the formation of water-soluble inclusion complexes in which apolar interior of the hollow, truncated cone-like CD structure encapsulates hydrophobic parts of drug molecules. CDs have already been proposed for lung administration [17] . Aqueous solutions of CD derivatives (hydroxypropyl-β-cyclodextrin (HPCD) and randomly methylated β-cyclodextrin (RAMEB) could be aerosolized with nebulizers commonly used in clinical practice, resulting in droplet size range compatible with pulmonary deposition. Additionally, the short-term exposure to inhaled HPβCD and RAMEB solutions was found to be non-toxic [18] .
The purpose of the present work was to study the complexation behavior of rifampicin with HPβCD or RAMEB in order to optimize the formulation of inclusion complexes and to demonstrate their usefulness in terms of rifampicin solubility enhancement. Then lung transport of rifampicin as complex with cyclodextrins was evaluated in an in vitro Calu-3 broncho-alveolar epithelial cell model [19] . Finally the antibacterial activity was assessed in vitro against A. Baumannii.
Materials and Methods

Materials
Rifampicin (≥ 97.0% (HPLC)) and fluorescein (sodium salt) were purchased from SigmaAldrich. 2-hydroxypropyl-β-cyclodextrin (HPβCD) with a degree of substitution per glucose unit of 0.6 -0.9 and a MW of 1510 g/mol (Kleptose ® HP) was obtained from Roquette.
Cavasol ® W7 M pharma, a randomly methylated β-cyclodextrin derivative (RAMEB) with a degree of substitution per glucose unit of 1.6 and with a MW of 1310 g/mol was obtained from Wacker. Cell culture media and supplements were from Hyclone. Phosphate buffered saline (PBS) tablets and all other chemicals of reagent grade were purchased from SigmaAldrich. Ultrapure water was produced by a Direct-Q water purification system (Millipore).
Rifampicin -CD complexation studies
Preliminary experiments were carried out in order to determine the optimal pH for the formation of complexes. An excess amount of rifampicin (until saturation) was added to 1 mL of 5% w/v of CD (0.033 M of HPβCD -0.038 M RAMEB) solutions buffered either at pH 4 with 0.05 M of citric acid/ sodium citrate, pH 7.4 with 0.05 M of PBS or pH 9 with 0.05 M of sodium tetraborate. Suspensions were stirred in a 37°C water bath for 7 days in order to reach equilibrium. Samples were filtered through a 0.2 μm syringe filter (Acrodisc  ). The first 500µL was discarded to avoid unspecific rifampicin membrane filter adsorption and the total rifampicin concentration was assayed in the remaining volume by HPLC. Each experiment was carried out in triplicate. Phase solubility diagrams were performed similarly by using 
Constants calculations
In the hypothesis that cyclodextrin-rifampicin complexes (CD-RIF) were of 1:1 stoichiometry, the apparent stability constant Ks was calculated using the following equation: 
Equation 2
Thus Ks was calculated as defined in equation 3, using the slope of the linear regression The complexation efficiency (CE), corresponding to the complex to free cyclodextrin concentration ratio, was calculated from the phase diagram slope according to equation 4 [20] .
Complex stability studies.
Solutions of complex formed with rifampicin (59 mM) and RAMEB (0.23 M) in 0.05 M of sodium tetraborate (pH 9) were diluted 6 times in Ringer-HEPES medium (pH 7.4) or in 0.1 M of citric acid/ citrate buffer (pH 4). These dilutions did not modify the initial pH of buffers.
After 1H or 2 days of stirring, solutions were filtered on 0.2 µm filter before rifampicin assay. Three inserts were used for each condition. In all cases, the amount of rifampicin transferred from the donor to the acceptor compartments never exceeded 5% of the input.
Calu
Fluxes J a-b in the apical-to-basal direction were calculated as follows:
where C a is the concentration in rifampicin and V a the volume (1 mL) of solution in the acceptor compartment, t the incubation time (60 min) and S the insert surface area (4.2 cm 2 ).
The total, i.e. filter-plus-cell, permeability coefficients (P Total ) for both rifampicin and fluorescein in the apical-to-basal direction were calculated using the following equation:
where C d is the initial concentration in the donor compartment. P Total is the resultant of epithelial cell barrier permeability P e and filter permeability P f . For diffusion through membranes in series, the mathematical relationship between permeability coefficients is: 1/P Total = 1/P e + 1/P f [21] . Therefore P e can be calculated from the formula:
1/P e = 1/P Total -1/P f . However, due to high values of fluorescein and rifampicin P f (131 ± 12 x 10 -6 and 139 ± 14 x 10 -6 cm/s respectively) compared to P Total , 1/P f was neglected and P e = P total . Mean P e value for 10µg/mL fluorescein (n = 6) was calculated to be 0.57  0.06 x 10 -6 cm/s with extremes of 0.40 -0.70 x 10 -6 cm/s. The threshold P e value of 0.7 x 10 -6 cm/s for fluorescein was retained for the tight junction integrity rejection parameter.
Determination of minimum inhibitory concentration (MIC) of rifampicin
MIC of rifampicin, free or after complexation with CD, was determined by a serial two-fold 
Rifampicin and fluorescein assay
Stock standard solution of rifampicin (2.8 mg/mL -3 mM) was prepared by dissolving 28 mg of rifampicin in 10 ml acetonitrile and was stored protected from light at -20°C. Stock 
Results -Discussions
Complexation studies
Rifampicin molecule (Fig.1) contains several ionizable groups leading to the formation of various ionic species as a function of pH. The two main ionizable groups between pH 1 and 11 are the hydroxyl in C4 and the 3'-piperazin nitrogen, with pKa of 1.7 and 7.9 respectively [22] . In order to evaluate the effect of rifampicin ionized groups on the formation of complexes with cyclodextrins, apparent rifampicin solubility values were determined at pH 4, 7.4 and 9 in the presence of 5% w/v of HPCD or RAMEB and compared to solubility of rifampicin alone. As shown on Fig. 2A , the rifampicin solubility was the lowest at pH 4 and increased with pH, as already described by Agrawal et al. [16] . This increase was of low magnitude between pH 4 and pH 7.4 (2-time increase) and higher from pH 7.4 to 9 (further 3.6-time increase). The increase in rifampicin solubility with pH may be related to the change in rifampicin ionization states. Indeed, three ionic species can be expected in the pH range 1-11; a cationic form predominating at pH < 1.7, a globally neutral zwitterionic form between pH 1.7 and pH 7.9 and an anionic form above 7.9 (Fig. 2B) . The lower solubility observed at pH 4 was attributed to predominant intra/intermolecular charge neutralization of zwitterions at the expense of interactions with water molecules. From pH 6 to 9, zwitterions are replaced by anionic rifampicin possessing higher solubility. In the presence of cyclodextrins, rifampicin apparent solubility also varied as a function of the pH ( Fig. 2A) . At pH 4, 5% w/v HPCD or RAMEB concentration had no effect on rifampicin apparent solubility, demonstrating an ineffective complexation. At pH 7.4, with 5% w/v of RAMEB, rifampicin apparent solubility was two times higher than rifampicin solubility, whereas HPCD at similar concentration had no effect. At pH 9, 5% of HPCD or RAMEB noticeably increased rifampicin apparent solubility. As proposed by Rao et al. [23] from I.R. spectroscopic measurements, rifampicin -CD interaction is mediated through the piperazin group. Increase in pH from 7.4 to 9 led to the deprotonation of the N-3' of the piperazin group (pKa 7.9) and favoured higher interaction between this group and the apolar interior of CD, as showed by the increase in rifampicin apparent solubility.
Shown to be favorable to the formation of rifampicin CD complexes, pH 9 was chosen to perform phase solubility diagrams (Fig 3) . In the 0 to 0.23 M RAMEB concentration range, the rifampicin apparent solubility increased linearly and corresponded to an A L type curve, suggesting the formation of 1/X (X  1) stoichiometry RAMEB/rifampicin complex [24] . As suggested above, the rifampicin piperazin group is internalized in CD. Due to the size of this group, only one piperazin group is likely to be included in the CD hydrophobic cavity and the hypothesis of 1/1 complex between RAMEB and rifampicin was made. In order to aerosolize the rifampicin complex solutions into the lungs, their pH (pH 9) need to be lowered to physiological pH (7.4). As this may result in complex destabilization and rifampicin precipitation, the physical stability of complexes was assessed after 1/6 th dilution in Ringer-HEPES medium pH 7.4 (Table 1) . After one hour in Ringer-HEPES pH 7.4, no loss of rifampicin due to precipitation was observed. After 2 days in pH 7.4, 97.9 % of rifampicin remained solubilized. Hence, rifampicin-CD complexes can be formulated at pH 9
for the best complexation efficiency and then extemporaneously buffered at pH 7.4 for their nebulisation in the lung. Further studies performed after dilution in citrate buffer pH 4 showed a rifampicin loss less than 5% after 1 hour and of 19.5% after 1 day. Rifampicin loss was attributed to rifampicin precipitation from supersaturated solutions. Supersaturation resulted from the dissociation of complexes induced by dilution and from a pH-related decrease in rifampicin solubility. Higher rifampicin loss observed at pH 4 compared to pH 7.4 could be attributed to the inability of CD to complex rifampicin at this pH as observed in Fig. 2A , due to the protonation of piperazin group of 100 % rifampicin molecules. (Fig. 3) , meaning that on average, about one out of four cyclodextrin molecules in solution forms a complex with one rifampicin molecule. The maximum amount of solid that can be administered in rat lungs is around 10 mg [25] . Therefore, the amounts of rifampicin contained in 10 mg of powder would be 1.36 mg and 1.20 mg, for RAMEB and HPCD complexes respectively, which is lower than with the complexes in solution. Furthermore, this amount of rifampicin is low in comparison to the aerosolization of 10 mg of pure rifampicin. However, due to higher solubility of the complex than free rifampicin, the solubilisation rate should be faster with the complex. As a consequence, the maximal rifampicin concentration reachable in the ELF could be higher when rifampicin will be administered as CD complex than pure.
Transport across an epithelial cell barrier model
The goal of our study was to increase rifampicin concentration in ELF. This concentration is a balanced value depending on the amount of rifampicin administered into the lung and its rate of elimination. The passive diffusion of molecules from the lung lumen to the blood is mainly limited by the lung epithelium, due to the presence of tight junctions between type I pneumocytes. In order to evaluate the effect of rifampicin complexation with CD upon its diffusion, we studied the rifampicin linear flux, as defined by Fick's law, under free and complexed form across a Calu-3 cell layer, an epithelial alveolar model forming high level of tight junction [19] .
HPCD and especially RAMEB are known to potentially reduce cell membrane viscosity due to cholesterol extraction, resulting in an increase in membrane permeability and cell toxicity [26] . Therefore, to assess the effects of CD on epithelial cells, the permeability of fluorescein In our studies, rifampicin permeability measured in the presence of HPCD or RAMEB was slightly lower (1.4 times) than with rifampicin alone, indicating that after 1 hour incubation
CDs did not increase rifampicin transcellular transport due to interactions with the epithelial cell membrane. The slightly lower permeability measured in presence of CDs was attributed to a complexation of the free rifampicin with CDs in the Ringer-HEPES medium, even though the ability of rifampicin to be complexed with CD was weak at pH 7.4.
As the presence of CDs did not modify the integrity of the cell monolayer in the timescale of 1 hour, rifampicin transport across the alveolar epithelial cell model was performed (Fig. 5) .
For all experiments, rifampicin fluxes were proportional to the total rifampicin concentration.
This suggests that at least in the rifampicin concentration ranges studied, in the presence or absence of CD, transport of rifampicin across the cell layer was a diffusion-driven process, excluding the involvement of membrane transporter [28] . As shown by the slopes of the curve in Figure 5 , for a given total concentration of rifampicin, flux values were lower with rifampicin complex than with rifampicin alone. Results also showed that rifampicin flux measured in presence of complex was independent of the nature of CDs.
Considering free rifampicin, permeability value (1.69  0.40 x 10 -6 cm/s) calculated from the slope of the linear regression of the rifampicin flux versus concentration curve (Fig.5) , was
close to values generally reported in literature across rat jejunum or ileum [28, 29] , or across Caco-2 cell monolayer model [30] (2 x 10 -6 cm/s). This value is lower than values observed on everted rat gut sac model for low permeable drugs listed by the US FDA (furosemide, ranitidine) [29] . This suggests that rifampicin is a drug with low lung permeability and hence qualifies to be used for lung-targeted aerosol therapy.
As shown on Figure 5 , the highest flux value found with free rifampicin alone was 5 x 10 -12 mol/cm 2 /s and was observed when rifampicin reached saturation concentration, i.e. 2.6 mM.
When rifampicin was complexed with RAMEB, this flux value was reached for a much higher total rifampicin concentration (21. 
Antibacterial activity
In the objective to evaluate the bacteriostatic activity of rifampicin complex, we measured the Hence, rifampicin-CD solutions had bacteriostatic activities against A. baumannii CIP7010T equivalent to (RAMEB) or higher than (HPCD) a solution of rifampicin alone, suggesting that the complexation process does not alter the rifampicin bacteriostatic activity. Similar results were found on in vitro anti-tubercular activity of rifampicin by Rao et al. [23] .
Complexation of rifampicin with β-CD or hydroxyl-ethyl-β-cyclodextrin reduced MIC values to half. Furthermore, considering that a fraction rifampicin was complexed with CD and that only the free fraction of rifampicin should be active, RAMEB and HPCD should improve rifampicin activity.
Conclusion
In the aim to improve treatment efficiency against pulmonary infections and avoid the apparition of MDR gram negative bacteria, a new rifampicin -cyclodextrin formulation was 
